Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | AMD1 | P17707 | 1/20 | 0.31 |
| ▸ | IARS1 | P41252 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RNMT | O43148 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12223717 | 0.83 | NT5E (0.43) | ADORA2AADORA2BNT5E | |
| SCHEMBL12667512 | 0.83 | NT5E (0.43) | ADORA2AADORA2BNT5E | |
| SCHEMBL13384043 | 0.83 | DOT1L (0.33) | DOT1LAHCYADORA2AADORA2BTRDMT1 | |
| SCHEMBL26554236 | 0.83 | PRMT6 (0.43) | — | |
| SCHEMBL20248724 | 0.83 | PRMT6 (0.43) | — | |
| SCHEMBL25808118 | 0.83 | PRMT6 (0.43) | — | |
| SCHEMBL18510956 | 0.83 | PRMT6 (0.43) | — | |
| SCHEMBL18521428 | 0.78 | ADORA1 (0.43) | ADORA2AADORA2BTP53 | |
| SCHEMBL29884287 | 0.77 | ADORA2A (0.44) | DOT1LADORA2AADORA2BSMN1; SMN2RNMT | |
| SCHEMBL19145880 | 0.77 | PRMT6 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | DOT1L 3191/4885AHCY 2830/4885ADORA2A 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.